TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1463171
Drug: Room temperature
Normalized name: ROOM DEODORIZER POWDER MENTOR #3202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room temperature local anaesthetic solution (25 degrees C)
Study: 19282124
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg lopinavir + 50 mg ritonavir tablet formulation
Study: 17975231
Drug: N-acetylcysteine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (100 mg/kg i.v. bolus, 20 mg/kg/hr infusion until four hours after cardiopulmonary bypass)
Study: 11041902
Drug: Meloxicam 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 3.75 mg/d
Study: 11041902
Drug: Meloxicam 7.5
Normalized name: meloxicam 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 7.5 mg/d
Study: 11041902
Drug: Meloxicam 15
Normalized name: meloxicam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 15 mg/d
Study: 11041902
Drug: Diclofenac 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 100 mg (50 mg twice daily)
Study: 8977598
Drug: Budesonide 800
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 800 micrograms twice daily plus terbutaline 1000 micrograms three times daily
Study: 30120640
Drug: Control (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0.9% saline injections)
Study: 24756739
Drug: Mat Pilates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mat Pilates programme (8 weeks, 3 times weekly)
Study: 24756739
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (maintained normal daily activities)
Study: 8640997
Drug: Diuretic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic therapy (hydrochlorothiazide plus amiloride)
Study: 8640997
Drug: Placebo transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo transdermal nitroglycerin
Study: 1639045
Drug: Glycogen depletion
Normalized name: glycogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycogen depletion treatment (exercise + low-carbohydrate high-fat diet)
Study: 1639045
Drug: Glycogen repletion
Normalized name: glycogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycogen repletion treatment (exercise + high carbohydrate diet)
Study: 1639045
Drug: Diet treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet treatment (low-carbohydrate high-fat diet alone)
Study: 24327422
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for spinal metastasis post-RCT
Study: 21904945
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control arm with access to an eJournal for medications, allergies, and diabetes management
Study: 19042044
Drug: 10 mg/d
Normalized name: Arixtra 10 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/d atorvastatin (statin group 1)
Study: 19042044
Drug: 20 mg/d
Normalized name: Valtoco, 20 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/d atorvastatin (statin group 2)
Study: 18779613
Drug: Oral etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral etoposide plus carboplatin (EC)
Study: 15925032
Drug: Intranasally administered
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasally administered Cholecystokinin (CCK)
Study: 10550374
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with three cycles of carboplatin/5-FU prior to surgery and radiotherapy (arm A)
Study: 8908387
Drug: Intraperitoneal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal insulin injection (0.15 units/kg body wt)
Study: 8908387
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin injection (0.15 units/kg body wt)
Study: 28207516
Drug: Weekly SMS
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly SMS interventions
Study: 21129337
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (5 g glucose, 0.5 U insulin)
Study: 21129337
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose (10 g glucose, 1 U insulin)
Study: 21129337
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (20 g glucose, 2 U insulin)
Study: 21129337
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses tested
Study: 11856075
Drug: Budesonide enema
Normalized name: budesonide Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide enema (2 mg/100 mL at bedtime)
Study: 11856075
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole (0.5 g b.d.)
Study: 9642517
Drug: C2: 200-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: C2: 200-400 ng/ml
Study: 9642517
Drug: C0: 100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: C0: 100-200 ng/ml
Study: 8608684
Drug: Diclofenac (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (50 mg three times daily)
Study: 2681495
Drug: Sodium meclofenamate
Normalized name: Meclofenamate Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium meclofenamate (Meclomen) 100 mg, p.os, t.i.d.
Study: 30532984
Drug: 36 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 Gy whole-breast and 40 Gy partial-breast radiotherapy (reduced-dose)
Study: 28398471
Drug: Higher amounts
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher amounts of joule energy and treatment planes
Study: 28398471
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment with lower joule energy and treatment planes
Study: 20888091
Drug: Iron (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron (100 mg/day as ferrous sulphate) and folic acid (500 μg/day) supplementation
Study: 20888091
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 mg cane sugar)
Study: 16413752
Drug: High-dose creatine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose creatine supplementation (20 g/d for 1 week)
Study: 16413752
Drug: Low-dose creatine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose creatine supplementation (5 g/d for 20 weeks)
Study: 8967707
Drug: Cloxacillin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cloxacillin alone (2 g intravenously every 4 hours for 14 days)
Study: 8967707
Drug: Cloxacillin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cloxacillin plus gentamicin (1 mg/kg intravenously every 8 hours for 7 days)
Study: 29949889
Drug: Low-molecular-weight Collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight Collagen peptide (LMWCP) 1000 mg once daily for 12 weeks
Study: 22694755
Drug: Steroid-free (SF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-free (SF) immunosuppression (subgroup under 5 years)
Study: 22694755
Drug: Steroid-based (SB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-based (SB) immunosuppression (subgroup under 5 years)
Study: 19962115
Drug: Group phone-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group phone-based treatment
Study: 19962115
Drug: Individual phone-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual phone-based treatment
Study: 10467921
Drug: Hypnotic suggestions
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic suggestions to decrease pain affect (Experiment one)
Study: 10467921
Drug: Hypnotic suggestions
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic suggestions to increase and decrease pain affect (Experiment two)
Study: 10467921
Drug: Hypnotic suggestions
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic suggestions to modulate sensory aspect of pain (Experiment three)
Study: 8546501
Drug: Drug use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug use during pregnancy
Study: 231914
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg tubocurarine
Study: 231914
Drug: 0.04 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04 mg/kg pancuronium bromide
Study: 22679722
Drug: Chinese medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medical facial mask (twice a week for 4 weeks)
Study: 22679722
Drug: 5% benzoyl
Normalized name: BENZOYL PEROXIDE 2.5 g in 100 mL TOPICAL SOAP [Benzoyl Acne Wash -2.5% Benzoyl Peroxide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% benzoyl peroxide gel (once in the evening for 4 weeks)
Study: 20885412
Drug: Xylitol chewing
Normalized name: xylitol Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol chewing gum twice a day after breakfast and lunch (G1)
Study: 20885412
Drug: Fluoride gel
Normalized name: Sodium Fluoride Gel
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride gel application (G4)
Study: 18163038
Drug: rTMS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTMS treatment for major depressive disorder (MDD)
Study: 2021297
Drug: Carbamazepine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (200 to 800 mg/d)
Study: 6122846
Drug: Freshly prepared
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freshly prepared penicillin-G solution administered as a bolus
Study: 6122846
Drug: Penicillin-G solution
Normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin-G solution stored for a few hours
Study: 31907027
Drug: Scalp acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scalp acupuncture combined with conventional rehabilitation treatment
Study: 31907027
Drug: Conventional rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional rehabilitation treatment alone
Study: 30232416
Drug: Circadian phase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Circadian phase (biological evening)
Study: 20500899
Drug: Vernonia cinerea
Normalized name: vernonia cinerea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vernonia cinerea (VC) supplement
Study: 20500899
Drug: Exercise with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise with VC supplement
Study: 17650659
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group vs control group
Study: 7750528
Drug: Intravesical bacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical bacillus Calmette‐Guerin (BCG) immunotherapy
Study: 7750528
Drug: Maintenance BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance BCG using three weekly treatments at 6-month intervals
Study: 2246098
Drug: Maharishi Amrit
Normalized name: Amrix
DrugBank: Cyclobenzaprine (DB00924)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maharishi Amrit Kalash (MAK) tablets, twice daily for six weeks
Study: 2246098
Drug: Placebo, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, twice daily for six weeks
Study: 27791311
Drug: Platelets rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelets rich plasma injections
Study: 24688618
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care (education, pharmacotherapy monitoring, detecting and solving drug related problems)
Study: 24688618
Drug: Standard pharmaceutical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pharmaceutical services (dispensing medicines with or without counseling)
Study: 16886928
Drug: Dipyridamole 0.142
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole 0.142 mg/kg per min administered intravenously
Study: 15363419
Drug: Intradiscal steroid
Normalized name: CHYMOPAPAIN 2nKatU/ML INTRADISCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradiscal steroid injections (ISI)
Study: 15363419
Drug: Epidural steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid injections (ESI) in patients with inflammatory end‐plate changes
Study: 15363419
Drug: Discography with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discography with or without intradiscal steroid
Study: 3874037
Drug: Fluoxetine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (30 or 60 mg) with ethanol (45 ml absolute alcohol per 70 kg body weight)
Study: 31679186
Drug: Control (current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (current antiretroviral therapy)
Study: 19590475
Drug: Nortriptyline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline (10 mg daily increment over 1 week to 50 mg)
Study: 17334477
Drug: Cabergoline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (0.5 mg once a week for 6 weeks)
Study: 17334477
Drug: Diphereline (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphereline (3.75 mg 4 times every 28 days)
Study: 14973304
Drug: Aprepitant 125
Normalized name: aprepitant 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant 125 mg p.o. on day 1 and 80 mg p.o. on days 2 and 3
Study: 11253520
Drug: One-stage ventro-dorsal
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-stage ventro-dorsal procedure in combination with VDS and MPDS
Study: 30197040
Drug: Intradermal BCG
Normalized name: Tice BCG Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal BCG vaccine prior to standard intravesical BCG
Study: 26210166
Drug: Intravenous fosaprepitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fosaprepitant 150 mg (NK1 group)
Study: 26210166
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg (ONS group)
Study: 24283179
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 20 mg/daily for ten days
Study: 18080059
Drug: Naltrexone (Revia)
Normalized name: naltrexone Oral Tablet [ReVia]
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone (Revia) or acamprosate (Campral) or both medications and/or placebos in combination with medical management (MM), with or without combined behavioral intervention (CBI)
Study: 18080059
Drug: CBI without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBI without MM or pills
Study: 17318795
Drug: Telmisartan (Telm)
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan (Telm) 80 mg + Rosiglitazone (RSG) 4 mg
Study: 17318795
Drug: Amlodipine (Aml)
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine (Aml) 10 mg + Rosiglitazone (RSG) 4 mg
Study: 1532336
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly amorolfine 5% nail lacquer
Study: 1532336
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly amorolfine 5% nail lacquer
Study: 29659913
Drug: Hydromorphone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (4 mg/day initially, adjusted as necessary)
Study: 29659913
Drug: Oxycodone hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone hydrochloride (10 mg/day initially, adjusted as necessary)
Study: 27801825
Drug: Food supplement
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food supplement containing 600 mg of α‐lipoic acid, 165 mg of L‐carnosin, 7.5 mg of zinc, and vitamins of group B
Study: 19929980
Drug: Irbesartan (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (150 mg/d, titrated to 300 mg/day)
Study: 19929980
Drug: Hydrochlorothiazide (HCTZ,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ, 12.5 mg/d, titrated to 25 mg/day)
Study: 16636232
Drug: IV recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV recombinant tissue plasminogen activator (rt‐PA) 0.9 mg/kg
Study: 10807491
Drug: Venlafaxine 375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 375 mg/day
Study: 9085388
Drug: Annual tuberculin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual tuberculin testing plus isoniazid (INH) preventive therapy
Study: 8138865
Drug: Combined behavioral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined behavioral therapy (relaxation training, temperature biofeedback, cognitive training)
Study: 8138865
Drug: Combined behavioral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined behavioral therapy
Study: 26698911
Drug: Myo-inositol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myo-inositol (2 g plus 200 μg folic acid twice a day)
Study: 26698911
Drug: Placebo (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (200 μg folic acid twice a day)
Study: 21612646
Drug: donepezil 23
Normalized name: donepezil 23 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: donepezil 23 mg/d
Study: 20826962
Drug: Etomidate 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate 0.2 mg/Kg
Study: 20826962
Drug: Midazolam 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.15 mg/Kg
Study: 20826962
Drug: Thiopentone 5
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone 5 mg/Kg
Study: 20826962
Drug: Propofol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1.5 mg/Kg
Study: 18796471
Drug: Amiodarone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (300 mg intravenous bolus after third unsuccessful shock)
Study: 16155274
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg Zn/d
Study: 10078604
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of HAV vaccination (25 units) at 0 and 24 weeks (Group 1)
Study: 10078604
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of HAV vaccination (25 units) at 0, 2, and 24 weeks (Group 2)
Study: 1869643
Drug: Controlled-release styrene-divinylbenzene
Normalized name: divinylbenzene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release styrene-divinylbenzene polymer system containing benzoyl peroxide
Study: 1869643
Drug: Topical lotion
Normalized name: Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lotion with freely dispersed benzoyl peroxide
Study: 1869643
Drug: Formulations containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulations containing entrapped benzoyl peroxide
Study: 7267678
Drug: hydrotalcite/dimethicone suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrotalcite/dimethicone suspension
Study: 7267678
Drug: magnesium hydroxide/aluminum
Normalized name: magnesium hydroxide/aluminum hydroxide 170-180 ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: magnesium hydroxide/aluminum hydroxide suspension
Study: 6741447
Drug: Paracetamol 500
Normalized name: Paracetamol 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 500 mg suppositories
Study: 6741447
Drug: Pentazocine 50
Normalized name: pentazocine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine 50 mg suppositories
Study: 6741447
Drug: Pentazocine 50
Normalized name: pentazocine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine 50 mg suppositories after halothane anaesthesia
Study: 6741447
Drug: Pentazocine 50
Normalized name: pentazocine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine 50 mg suppositories after enflurane anaesthesia
Study: 6741447
Drug: Paracetamol 500
Normalized name: Paracetamol 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 500 mg suppositories after enflurane anaesthesia
Study: 6741447
Drug: Paracetamol 500
Normalized name: Paracetamol 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 500 mg suppositories after halothane anaesthesia
Study: 29843528
Drug: Writing about
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Writing about daily events
Study: 23617557
Drug: One-step method
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-step method (2-h, 75 g oral glucose tolerance test)
Study: 23617557
Drug: Two-step method
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two-step method (50 g glucose challenge test followed by 100 g OGTT)
Study: 23588128
Drug: Self-administered paper-and-pencil
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered paper-and-pencil questionnaire measuring perceived risk for STIs
Study: 21174921
Drug: No steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: No steroids (Control group)
Study: 19094438
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg levobupivacaine 0.5% mixed with 25 microg fentanyl (group LF)
Study: 19094438
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg levobupivacaine 0.5% (group L)
Study: 10924301
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium (10.3 mmol)
Study: 10924301
Drug: Sotalol and
Normalized name: sotalol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol and oral magnesium